Clinical impact of febrile neutropenia (FIN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer

被引：0
|
作者：
Hamilton, Erika Paige
Topping, Donna L.
Peppercorn, Jeffrey M.
Marcom, P. Kelly
Kimmick, Gretchen Genevieve
Duff, Erin
Cirrincione, Constance T.
Blackwell, Kimberly L.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Duke Canc Inst Biostat, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1076
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Febrile neutropenia and primary prophylactics in docetaxel plus cyclophosphamide chemotherapy for breast cancer: A Japanese institution experience
    Kimura, Y.
    Sasada, S.
    Goda, N.
    Emi, A.
    Kajitani, K.
    Masumoto, N.
    Haruta, R.
    Kadoya, T.
    Kataoka, T.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer
    Yu, Joanne L.
    Chan, Kelvin
    Kurin, Michael
    Pasetka, Mark
    Kiss, Alex
    Sridhar, Srikala S.
    Warner, Ellen
    BREAST JOURNAL, 2015, 21 (06): : 658 - 664
  • [23] Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study
    Zhang, Zhisheng
    Li, Huan
    Zhang, Jiacheng
    Ye, Xuan
    Liu, Hongyue
    Zhai, Qing
    Yu, Bo
    Du, Qiong
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5310 - 5315
  • [24] Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy
    Alexandre Chan
    Wing Hang Fu
    Vivianne Shih
    Jurja Chua Coyuco
    Sze Huey Tan
    Raymond Ng
    Supportive Care in Cancer, 2011, 19 : 497 - 504
  • [25] Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy
    Chan, Alexandre
    Fu, Wing Hang
    Shih, Vivianne
    Coyuco, Jurja Chua
    Tan, Sze Huey
    Ng, Raymond
    SUPPORTIVE CARE IN CANCER, 2011, 19 (04) : 497 - 504
  • [26] Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
    Kim, Chang Gon
    Sohn, Joohyuk
    Chon, Hongjae
    Kim, Joo Hoon
    Heo, Su Jin
    Cho, Hyunsoo
    Kim, In Jung
    Kim, Seung Il
    Park, Seho
    Park, Hyung Seok
    Kim, Gun Min
    JOURNAL OF BREAST CANCER, 2016, 19 (01) : 76 - 82
  • [27] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Yoshimasa Kosaka
    Yoshiaki Rai
    Norikazu Masuda
    Toshimi Takano
    Toshiaki Saeki
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Yutaka Tokuda
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 1137 - 1143
  • [28] RATE OF FEBRILE NEUTROPENIA WITH DOCETAXEL/CYCLOPHOSPHAMIDE (TC) IN WOMEN WITH EARLY STAGE BREAST CANCER: AN AUSTRALIAN PUBLIC HOSPITAL EXPERIENCE
    Pokharel, K.
    Lovat, K.
    Chern, B.
    Bigby, K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 42 - 42
  • [29] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Kosaka, Yoshimasa
    Rai, Yoshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Saeki, Toshiaki
    Nakamura, Seigo
    Shimazaki, Ryutaro
    Ito, Yoshinori
    Tokuda, Yutaka
    Tamura, Kazuo
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1137 - 1143
  • [30] Time to first febrile neutropenia among early stage breast cancer patients receiving adjuvant chemotherapy.
    Scott, SD
    Chrischilles, EA
    Link, BK
    Delgado, DJ
    Fridman, M
    Lyman, GH
    PHARMACOTHERAPY, 2003, 23 (03): : 406 - 406
12345